Drugs / SPC5001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01350960 | May → Oct 2011 | familial hypercholesterolemia | Santaris Pharma A/S | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPC5001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01350960 ↗ |
| Action | Inhibit | “SPC5001 treatment dose-dependently inhibited PCSK9” PMID 26261033 ↗ Oct 2015 |
| Modality | Antisense oligonucleotide | “SPC5001, a locked nucleic acid antisense inhibitor of PCSK9.” PMID 26261033 ↗ Oct 2015 |
| Route | Subcutaneous | “three weekly subcutaneous administrations of SPC5001” PMID 26261033 ↗ Oct 2015 |
| Target | PCSK9 | “target protein PCSK9” PMID 26261033 ↗ Oct 2015 |